Cargando…
Acute presentation of vasospastic angina induced by oral capecitabine: a case report
INTRODUCTION: Oral capecitabine is an oral prodrug of 5-fluorouracil that has been integrated into the management of multiple cancer types because of the convenience of administration and its efficacy compared with 5-fluorouracil. Capecitabine mimics the pharmacokinetics of intravenous 5-fluorouraci...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923566/ https://www.ncbi.nlm.nih.gov/pubmed/24428956 http://dx.doi.org/10.1186/1752-1947-8-18 |
_version_ | 1782303627628511232 |
---|---|
author | Golias, Christos Dimitriadis, Georgios Dimitriadis, Dimokritos Graidis, Christos Dimitrelos, Ilias Tsiakou, Afroditi Bitsis, Theodosis Charalabopoulos, Konstantinos |
author_facet | Golias, Christos Dimitriadis, Georgios Dimitriadis, Dimokritos Graidis, Christos Dimitrelos, Ilias Tsiakou, Afroditi Bitsis, Theodosis Charalabopoulos, Konstantinos |
author_sort | Golias, Christos |
collection | PubMed |
description | INTRODUCTION: Oral capecitabine is an oral prodrug of 5-fluorouracil that has been integrated into the management of multiple cancer types because of the convenience of administration and its efficacy compared with 5-fluorouracil. Capecitabine mimics the pharmacokinetics of intravenous 5-fluorouracil. While cardiac events associated with the use of 5-fluorouracil are a well-known side effect, capecitabine-induced cardiotoxicity has only been rarely reported. CASE PRESENTATION: We present a case of a 46-year-old woman of Greek ethnicity who presented to our institution with an operated gastric sarcoma who experienced capecitabine-induced vasospastic angina. Primarily a clinical diagnosis of a possible acute coronary syndrome was proposed and the patient was admitted to the hospital for further investigation which was proved between normal limits. After a witnessed episode of angina, her prior history of capecitabine intake and an undertaken further imaging investigation we associated anginal symptoms and signs with vasospastic angina induced by capecitabine 36 hours prior to hospital admission. CONCLUSION: Cardiologists should be aware of the potential cardiac hazards of capecitabine, especially in patients with cardiovascular risk factors. Due to the increasing usage of capecitabine during the last years, patients should be warned for the possibility of chest pain, particularly during the first few days of capecitabine treatment. Specifically, patients developing acute coronary syndrome should not be retreated with capecitabine. On the other hand, due to its promising antitumoral efficacy, its use should not be discouraged. |
format | Online Article Text |
id | pubmed-3923566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39235662014-02-14 Acute presentation of vasospastic angina induced by oral capecitabine: a case report Golias, Christos Dimitriadis, Georgios Dimitriadis, Dimokritos Graidis, Christos Dimitrelos, Ilias Tsiakou, Afroditi Bitsis, Theodosis Charalabopoulos, Konstantinos J Med Case Rep Case Report INTRODUCTION: Oral capecitabine is an oral prodrug of 5-fluorouracil that has been integrated into the management of multiple cancer types because of the convenience of administration and its efficacy compared with 5-fluorouracil. Capecitabine mimics the pharmacokinetics of intravenous 5-fluorouracil. While cardiac events associated with the use of 5-fluorouracil are a well-known side effect, capecitabine-induced cardiotoxicity has only been rarely reported. CASE PRESENTATION: We present a case of a 46-year-old woman of Greek ethnicity who presented to our institution with an operated gastric sarcoma who experienced capecitabine-induced vasospastic angina. Primarily a clinical diagnosis of a possible acute coronary syndrome was proposed and the patient was admitted to the hospital for further investigation which was proved between normal limits. After a witnessed episode of angina, her prior history of capecitabine intake and an undertaken further imaging investigation we associated anginal symptoms and signs with vasospastic angina induced by capecitabine 36 hours prior to hospital admission. CONCLUSION: Cardiologists should be aware of the potential cardiac hazards of capecitabine, especially in patients with cardiovascular risk factors. Due to the increasing usage of capecitabine during the last years, patients should be warned for the possibility of chest pain, particularly during the first few days of capecitabine treatment. Specifically, patients developing acute coronary syndrome should not be retreated with capecitabine. On the other hand, due to its promising antitumoral efficacy, its use should not be discouraged. BioMed Central 2014-01-15 /pmc/articles/PMC3923566/ /pubmed/24428956 http://dx.doi.org/10.1186/1752-1947-8-18 Text en Copyright © 2014 Golias et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Golias, Christos Dimitriadis, Georgios Dimitriadis, Dimokritos Graidis, Christos Dimitrelos, Ilias Tsiakou, Afroditi Bitsis, Theodosis Charalabopoulos, Konstantinos Acute presentation of vasospastic angina induced by oral capecitabine: a case report |
title | Acute presentation of vasospastic angina induced by oral capecitabine: a case report |
title_full | Acute presentation of vasospastic angina induced by oral capecitabine: a case report |
title_fullStr | Acute presentation of vasospastic angina induced by oral capecitabine: a case report |
title_full_unstemmed | Acute presentation of vasospastic angina induced by oral capecitabine: a case report |
title_short | Acute presentation of vasospastic angina induced by oral capecitabine: a case report |
title_sort | acute presentation of vasospastic angina induced by oral capecitabine: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923566/ https://www.ncbi.nlm.nih.gov/pubmed/24428956 http://dx.doi.org/10.1186/1752-1947-8-18 |
work_keys_str_mv | AT goliaschristos acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport AT dimitriadisgeorgios acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport AT dimitriadisdimokritos acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport AT graidischristos acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport AT dimitrelosilias acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport AT tsiakouafroditi acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport AT bitsistheodosis acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport AT charalabopouloskonstantinos acutepresentationofvasospasticanginainducedbyoralcapecitabineacasereport |